Eftihia Davelis
Family Medicine · Yorkville, ILNPI 1669977948
Payments from drug & device makers
Across 341 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$875
- Novo Nordisk$800
- AbbVie$645
- Amgen$591
- Pfizer$470
- AstraZeneca$414
- plus $2K from 22 others
What the payments were for
- Food & beverage$6,014100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 45 | $875 |
| Novo Nordisk | 53 | $800 |
| AbbVie | 38 | $645 |
| Amgen | 32 | $591 |
| Pfizer | 25 | $470 |
| AstraZeneca | 26 | $414 |
| Lilly USA, LLC | 24 | $366 |
| GSK | 12 | $269 |
| Merck | 15 | $237 |
| Exact Sciences | 9 | $196 |
| Novartis | 12 | $158 |
| Gilead | 8 | $137 |
| Cranial Technologies, Inc | 7 | $121 |
| E.r. Squibb & Sons, L.L.C. | 7 | $112 |
| Sanofi Pasteur Inc. | 4 | $106 |
| Astellas Pharma US Inc | 5 | $91 |
| Sanofi-aventis U.S. LLC | 3 | $82 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $51 |
| Dynavax Technologies Corporation | 2 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $45 |
| Hologic Sales And Service, LLC | 2 | $35 |
| Bayer | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Edwards Lifesciences | 1 | $25 |
| Abbott | 1 | $23 |
| Avanos Medical | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $18 |
How this compares
$6,014 in reported general payments places this provider in the 90th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 26 | $44,811 |
| JanuviaSitagliptin Phosphate | 22 | $30,468 |
| EliquisApixaban | 20 | $22,906 |
| MounjaroTirzepatide | 14 | $20,208 |
| OzempicSemaglutide | 21 | $19,864 |
| TrulicityDulaglutide | 16 | $17,520 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,800 |
| Spiriva RespimatTiotropium Bromide | 14 | $7,256 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $5,371 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,602 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,568 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,298 |
| Atorvastatin Calcium | 286 | $3,125 |
| Levothyroxine Sodium | 269 | $2,790 |
| Metoprolol Succinate | 129 | $2,356 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $875 | $52,06740 claims |
| Lilly USA, LLCMounjaro, Trulicity | $366 | $37,72830 claims |
| MerckJanuvia | $237 | $30,46822 claims |
| PfizerEliquis | $470 | $22,90620 claims |
| Novo NordiskOzempic | $800 | $19,86421 claims |
| GSKBreo Ellipta, Incruse Ellipta | $269 | $11,40222 claims |
| AstraZenecaSymbicort | $414 | $3,29815 claims |
| AbbVieSynthroid | $645 | $1,69421 claims |
| Sanofi-aventis U.S. LLCLantus | $82 | $75112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Yorkville
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.